BioTelemetry, Inc. (NASDAQ:BEAT), today reported results for the third quarter ended September 30, 2016. Company Highlights include: Recognized highest quarterly revenue in Company’s history of $53.1 million, a 22% increase over the prior year. Recorded $4.1 million GAAP net income for the third quarter. Realized highest quarterly adjusted EBITDA in Company’s history of $12.2 million, a 40% increase over the prior year. Experienced 9% year over year growth in patient volume and much more.

BioTelemetry, Inc. (NASDAQ:BEAT) will release its third quarter 2016 earnings on Wednesday, November 2, 2016 at 4:00 PM Eastern Time. The BioTelemetry quarterly conference call will be held at 5:00 PM Eastern Time, Wednesday, November 2, 2016. The broadcast will be available through the investor information section of the BioTelemetry website www.gobio.com.

BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, is pleased to announce that the Company has received CE mark approval of its Holter analysis software.

BioTelemetry, Inc. (NASDAQ:BEAT), is pleased to announce that it has entered into a strategic partnership with Bloom Technologies, Inc. (“Bloomlife”), an early stage digital health company.

BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the second quarter ended June 30, 2016.

BioTelemetry, Inc. (NASDAQ:BEAT) will release its second quarter 2016 earnings on Tuesday, August 2, 2016 at 4:00 PM Eastern Time. The BioTelemetry quarterly conference call will be held at 5:00 PM Eastern Time, Tuesday, August 2, 2016. The broadcast will be available through the investor information section of the BioTelemetry website www.gobio.com.

BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, is pleased to announce that it has received U.S. Food and Drug Administration (“FDA”) 510(k) clearance of its next generation Mobile Cardiac Outpatient Telemetry™ device, the MCOT™ Patch.

BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today that it has completed its acquisition of VirtualScopics, Inc. (NASDAQ:VSCP), a leading provider of clinical trial imaging solutions.

BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the first quarter ended March 31, 2016.